Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
暂无分享,去创建一个
K. Beusterien | R. Stone | K. McLaurin | S. Amin | M. Cambron-Mellott | M. Monberg | M. Maculaitis | E. Szamreta | E. Mulvihill | S. Ritz